ES2187184T3 - Fosfoepoxidos, procedimiento de fabricacion y aplicaciones. - Google Patents

Fosfoepoxidos, procedimiento de fabricacion y aplicaciones.

Info

Publication number
ES2187184T3
ES2187184T3 ES99940246T ES99940246T ES2187184T3 ES 2187184 T3 ES2187184 T3 ES 2187184T3 ES 99940246 T ES99940246 T ES 99940246T ES 99940246 T ES99940246 T ES 99940246T ES 2187184 T3 ES2187184 T3 ES 2187184T3
Authority
ES
Spain
Prior art keywords
phosfoepoxides
applications
manufacturing procedure
formula
phosphopoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99940246T
Other languages
English (en)
Inventor
Christian Belmant
Jean-Jacques Fournie
Marc Bonneville
Marie-Alix Peyrat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2187184T3 publication Critical patent/ES2187184T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que comprenden por lo menos un grupo fosfoepóxido de fórmula: **(Fórmula)** en el que R1 es elegido entre -CH3 y -CH2 -CH3, Cat+ es un catión orgánico o mineral, n es un número entero comprendido entre 2 y 20, para su utilización en concepto de sustancias terapéuticamente activas.
ES99940246T 1998-09-01 1999-08-27 Fosfoepoxidos, procedimiento de fabricacion y aplicaciones. Expired - Lifetime ES2187184T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810914A FR2782722B1 (fr) 1998-09-01 1998-09-01 Nouveaux composes phosphoepoxydes, procede de fabrication et applications

Publications (1)

Publication Number Publication Date
ES2187184T3 true ES2187184T3 (es) 2003-05-16

Family

ID=9530020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99940246T Expired - Lifetime ES2187184T3 (es) 1998-09-01 1999-08-27 Fosfoepoxidos, procedimiento de fabricacion y aplicaciones.

Country Status (12)

Country Link
US (2) US7101711B1 (es)
EP (1) EP1109818B1 (es)
JP (1) JP2002523515A (es)
AT (1) ATE227296T1 (es)
AU (1) AU5426599A (es)
CA (1) CA2341578A1 (es)
DE (1) DE69903838T2 (es)
DK (1) DK1109818T3 (es)
ES (1) ES2187184T3 (es)
FR (1) FR2782722B1 (es)
PT (1) PT1109818E (es)
WO (1) WO2000012519A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2791981B1 (fr) 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
CA2564562A1 (en) * 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
WO2007039635A2 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications

Also Published As

Publication number Publication date
DE69903838D1 (de) 2002-12-12
EP1109818B1 (fr) 2002-11-06
US20060287274A1 (en) 2006-12-21
DK1109818T3 (da) 2003-03-03
EP1109818A1 (fr) 2001-06-27
CA2341578A1 (fr) 2000-03-09
FR2782722B1 (fr) 2001-01-12
US7101711B1 (en) 2006-09-05
DE69903838T2 (de) 2003-07-10
WO2000012519A1 (fr) 2000-03-09
FR2782722A1 (fr) 2000-03-03
AU5426599A (en) 2000-03-21
PT1109818E (pt) 2003-02-28
JP2002523515A (ja) 2002-07-30
US7432253B2 (en) 2008-10-07
ATE227296T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
ES2178459T3 (es) Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones.
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
BR9900320A (pt) Composição antimicrobiana
GT199800207A (es) Nuevos derivados de la eritromicina.
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
ES2187184T3 (es) Fosfoepoxidos, procedimiento de fabricacion y aplicaciones.
BRPI9915822B8 (pt) derivados de pirazolopirimidinona e sua composição farmacêutica para o tratamento de impotência
CR6592A (es) Compuestos para el tratamiento de la isquemia
ES2196630T3 (es) Isotiazolcarboxiamidas y su empleo para la proteccion de las plantas.
BR9815464A (pt) Polìmero, processo de preparação de polìmeros, utilização de um polìmero, composição, associação de pelo menos um polìmero com pelo menos um composto e composição cosmética
ES2092345T3 (es) Compuestos organicos de silicio que contienen radicales glicosido, y procesos para su preparacion.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
FI940012A (fi) Aryylisulfonamidosubstituoidut hydroksaamihapot
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
BR9710841A (pt) Inibidores da metalproteinase matricial de bifenil-sulfonamida
CO5180587A1 (es) Composicion farmaceutica de orlistat que contiene tensoactivos y dispersantes
ES2188795T3 (es) Agentes antimicrobianos benzoxacina.
AR024138A1 (es) Inhibidores de la proliferacion celular
NO20005793L (no) Sammensetninger som inneholder organisk mono- eller dinitrat for behandling av impotens
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
BR0114813A (pt) Soluções farmacêuticas de compostos de modafinila e seu uso
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
BR0212535A (pt) Compostos e composições como inibidores de catepsina